Objective-We assessed whether the association between dietary saturated fatty acids (SFA) and incident coronary heart disease (CHD) depends on the food source, the carbon chain length of SFA, and the substituting macronutrient. Approach and Results-From the Rotterdam Study, 4722 men and women (≥55 years) were included. Baseline (1990Baseline ( -1993 SFA intake was assessed using a validated food frequency questionnaire. CHD (nonfatal myocardial infarction and fatal CHD) was ascertained by medical records. Using multivariable Cox regression analysis, we calculated CHD risks for higher intakes of total SFA, SFA from specific food sources, SFA differing in carbon chain length, and substituting other macronutrients instead of SFA. During a median follow-up of 16.3 years, 659 CHD events occurred. Total SFA intake was not associated with CHD risk (hazard ratio [HR] per 5 en%, 1.13; 95% confidence interval, 0.94-1.22), and neither was SFA from specific food sources. A higher CHD risk was observed for palmitic acid (16:0) intake (HR SD , 1.26; 95% confidence interval, 1.05-1.15) but not for SFA with other chain lengths. Except for a higher CHD risk for substitution of SFA with animal protein (HR 5en% , 1.24; 95% confidence interval, 1.01-1.51), substitution with other macronutrients was not associated with CHD. Conclusions-In this Dutch population, we observed that a higher intake of palmitic acid, which accounts for ≈50% of the total SFA intake, was associated with a higher CHD risk, as was substitution of total SFA with animal protein. Nevertheless, we found no association between total SFA intake and CHD risk, which did not differ by food source. (Arterioscler
T he classic hypothesis that dietary saturated fatty acids (SFA) increase low-density lipoprotein cholesterol levels and thereby the risk of coronary heart disease (CHD) remains controversial. 1 Three recent meta-analyses, including a total of 22 prospective cohort studies, did not confirm an association between SFA intake and CHD risk. [2] [3] [4] However, these studies focused solely on total SFA intake, neglecting other factors that should be considered: the food source of SFA, the differences in carbon chain lengths of SFA, and the substituting macronutrients. To illustrate, the MESA (Multi-Ethnic Study of Atherosclerosis) study observed a significantly lower CHD risk for people with a higher intake of SFA from milk but not from other sources. 5 Furthermore, in the NHS (Nurses' Health Study), associations with CHD differed for intakes of short-to-medium, even-chained SFAs (butyric acid (4:0) to capric acid (10:0)) as compared with the SFA with longer even-chained SFAs (lauric acid (12:0) to stearic acid (18:0)), 6 showing a significantly higher CHD risk for the latter only. Regarding the substituting macronutrient, cohort studies [7] [8] [9] and trials 10, 11 generally showed that the isocaloric substitution of SFA with polyunsaturated fatty acids (PUFA) may have beneficial effects on CHD risk, [7] [8] [9] [10] [11] whereas the substitution of SFA with carbohydrates seems to have no 9 or an adverse association 8 with CHD. For the substitution of SFA with monounsaturated fatty acids (MUFA), the results are inconclusive up to now, showing both protective 9 and adverse 8 associations with CHD risk.
Despite the recommendation in nutrition guidelines to lower dietary SFA, the intake is still high in many countries, including The Netherlands. 12 According to the food consumption surveys, 13, 14 ≈90% of the Dutch population exceeds the recommended upper intake limit of 10 en% of SFA per day, with dairy products providing ≈30% of the total SFA intake. 13, 14 In contrast to what could be expected, a higher SFA intake was recently associated with a significantly lower CHD risk in a Dutch cohort study, mainly driven by SFA from dairy products and SFA subtypes that are primarily derived from dairy. 15 Thus, the association between SFA and CHD risk may depend on type and source of SFA. Nevertheless, the evidence on the association between intake of individual SFAs and SFA from specific food sources is limited. Elucidating the role of different sources of SFA is important for shaping future dietary guidelines, because many recent dietary guidelines are food based. Therefore, we aimed to investigate the association between intake of total SFA, SFA from specific food sources, SFAs differing in carbon chain lengths and CHD. Furthermore, we investigated the association between SFA and CHD, taking into account substitution with other macronutrients. For these purposes, we used data from the Rotterdam study, a Dutch cohort consisting of middle-aged and elderly men and women.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Population Characteristics
Subjects in the higher quintiles of SFA intake (in en%) were older, more often women and smoker, less educated, and less physically active (Table 1 ). Furthermore, these participants had higher intakes of PUFA, cis-MUFA, trans-fat, and cholesterol and lower intakes of vegetable protein, carbohydrates, fiber, and vitamin C. With the exception of lauric acid (12:0) (r<0.41), the intakes of the individual SFAs were highly correlated (Table IV in the online-only Data Supplement). The highest correlations were observed for C14:0 and the sum of C15:0 and C17:0 (r=0.88), for palmitic acid and stearic acid (r=0.84), and for C14:0 and palmitic acid (r=0.80). The top 5 food sources of total SFA intake were cheese (20.0%), meat (17.8%), milk (13.1%), solid fats (12.3%) and cakes and cookies (10.1%; Figure 1 ). Approximately 74% of total SFA intake consisted of the long-chain SFAs palmitic acid and stearic acid ( Figure 2 ). The top food source of palmitic and stearic acid was meat, and the top food sources of all other SFA were milk and cheese (Figure I in the online-only Data Supplement).
SFA Intake and CHD Incidence
During a median follow-up of 16.3 years (interquartile range, 10-18), 569 CHD events occurred. Table 2 shows the hazard ratios (HRs) for the association between total SFA per 5 en% of intake and incident CHD risk. After adjustment for age, sex, and lifestyle, and dietary risk factors (model 3), intake of total SFA was not significantly associated with CHD (HR per 5 en%, 1.13; 95% confidence interval [CI], 0.94-1.36). Table 3 shows no significant associations between SFA from specific food groups and risk of CHD after multivariable adjustment (model 3). The HRs ranged from 1.03 to 1.08 (P>0.46), except for the HR for SFA from meat, which was 1.09 per SD of intake (95% CI, 0.99-1.20; P=0.10). With respect to the individual SFAs differing in carbon chain length ( Table 2) , no statistically significant associations with CHD risk were observed (model 3), except for palmitic acid, which was associated with a higher CHD risk of 26% (95% CI, 1.05-1.52) per SD of additional intake. For stearic acid, we observed a nonsignificant HR of 1.11 (95% CI, 0.98-1.25) per SD. Table 4 presents the estimated HR for 5% lower intake of energy from SFA and a concomitant higher intake of energy from other macronutrients. No statistically significant associations with incident CHD were observed for substitution of SFA with carbohydrates, cis-MUFA, and PUFA. The results for substitution of SFA with carbohydrates, while taking into account the glycemic index of the diet, did not differ from the results for substitution with total carbohydrates. Neither did substitution with carbohydrates from whole grains (HR 5en% , 0.78; 95% CI, 0.53-1.15) or with carbohydrates from refined starch and sugars (HR 5en% , 0.85; 95% CI, 0.60-1.20). Distinguishing between animal and vegetable protein showed that substitution of SFA with animal protein was significantly associated with an increased CHD risk (HR 5en% , 1.24; 95% CI, 1.01-1.51), whereas substitution with vegetable protein was not (HR 5en% , 0.88; 95% CI, 0.50-1.53).
Intake of SFA From Specific Food Sources or Differing in Carbon Chain Length and CHD Incidence
Substitution of SFA Intake With Other Macronutrients and CHD Incidence
Additional Analyses
Exclusion of the first 2-year follow-up did not alter the results (data not shown). However, in repeat analysis within the first 8 years, during which 222 CHD events occurred, we observed a significantly higher CHD risk of 16% for SFA from meat (HR per SD, 1.16; 95% CI, 1.00-1.34; P=0.045; Table V in the online-only Data Supplement). Also, we observed a significantly lower risk of CHD for a higher intake of SFA from cakes and cookies (HR SD , 0.76; 95% CI, 0.64-0.90). Furthermore, CHD risks were higher and statistically significant for intakes of palmitic acid (HR SD , 1.62; 95% CI, 1.23-2.15) and stearic acid (HR SD , 1.22; 95% CI, 1.01-1.47; Table VI in the online-only Data Supplement). Similarly, significantly higher CHD risks were observed for substitution of SFA with cis-MUFA (HR 5en% , 1.36; 95% CI, 1.14-1.62) and animal protein (HR 5en% , 1.54; 95% CI, 1.14-2.07; Table VII 
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Discussion
In this prospective cohort study, total SFA was not associated with incident CHD risk, and differentiation of SFA intake according to food sources had no conclusive effect on the association. Higher intake of palmitic acid, which contributes ≈50% of the total SFA intake, was associated with a higher risk of CHD, whereas SFAs with other carbon chain lengths were not. Aside from the significantly higher CHD risk for substitution of SFA with animal protein, substitution with other macronutrients was not associated with CHD.
A recent study estimated that 9.5% of annually occurring CHD deaths in The Netherlands were attributable to a nonoptimal SFA intake (>10 en% per day). 16 In this study, we observed no association between total dietary SFA and incident CHD, which is in line with the results of 3 recent meta-analyses. [2] [3] [4] However, when we separated SFA based on carbon chain length, we found a harmful association with palmitic acid, the predominant type of SFA in the diet. This is in line with the results from the NHS 6 but differs from those of the EPIC-NL cohort (European Investigation into Cancer and Nutrition-Netherlands), 15 in which palmitic acid was not associated with CHD, but a significant inverse association was observed for the short-to medium-chained SFAs. 15 Inverse associations were also observed before between circulating very longchain SFAs (with ≥20 carbons) and CHD risk. 17 However, we cannot directly compare these latter findings to the findings of our study because very long-chain SFAs are primarily synthesized in vivo from very long-chain unsaturated fatty acids. Therefore, these very long-chain SFAs may represent a different type of diet than a diet high in SFAs. We found no associations of SFA according to food source, including dairy products. In contrast, EPIC-NL, 15 and the MESA study, 5 found inverse associations with SFA from dairy products. Especially, the discrepancies with the EPIC-NL cohort are noteworthy. Similar to the Rotterdam Study, the EPIC-NL cohort consists of Dutch men and women, who were recruited in the early 1990s. Other similarities between the 2 cohorts include the use of a food frequency questionnaire (FFQ) to measure dietary intake and the use of the national nutrient database of 1998 for the calculation of SFA consumption. Furthermore, the intakes of total SFA and SFA subtypes were comparable between the 2 cohorts. One may speculate what explains the difference in results between our study and EPIC-NL. They may, at least in part, be explained by residual confounding because of differences in socioeconomic factors, which are reflected by the higher age, lower level of education, and higher BMI in our study. Another explanation could be the difference between the FFQs. In both cohorts, the top contributor to the mean palmitic acid intake was meat, providing ≈22% of its intake. In both cohorts, the association between meat-derived SFA and CHD was nonsignificant. Nevertheless, although in EPIC-NL the estimated CHD risk for higher intake of SFA from meat was null, in our study we observed a nonsignificantly higher risk of 9%, which became stronger (16%) and statistically significant for a shorter follow-up time of 8 years. This discrepancy may be explained by the fact that our FFQ included more detail on meat intake (34 single items and an open field to fill in types of cold cuts) than the FFQ used in EPIC-NL (8 aggregated items). This may have led to less nondifferential misclassification based on meat intake in this study as compared with EPIC-NL, which could explain why we were able to pick up both the association with palmitic acid and the suggestive association with meat-derived SFAs. Moreover, we observed a significantly higher CHD risk for substitution of SFA with animal protein but not vegetable protein. Together with the results for palmitic acid and for meat-derived SFA, it could be argued that these 3 risk estimates all reflect harmful effects of meat or meat-derived nutrients.
Apart from the results of the EPIC-NL study 15 and of a meta-analysis of secondary prevention trials, 18 the evidence from trials 10, 11, 19 and observational studies [7] [8] [9] up to now suggests that substitution of SFA with PUFA could provide cardiovascular benefits. Although we observed no significant association between the substitution of SFA with PUFA and CHD, our effect estimate is in line with these findings. One could question whether we had limited power to detect statistical significance, because some of the previous studies 8, 9 included a 10-fold of the number of events in our study. Our effect estimate for the substitution of SFA with cis-MUFA is also in line with the results of a pooled analysis (HR 5en% , 1.19; 95% CI, 1.00-1.42) 8 but in contrast to the significantly lower CHD risk observed for substitution of SFA with MUFA in a recent analysis in NHS and HPFS (HR 5en% , 0.85; 95% CI, 0.74-0.97). 9 Remarkably, we observed a statistically significant and much higher CHD risk for substitution of SFA with cis-MUFA (HR 5en% , 1.36; 95% CI, 1.14-1.62) in sensitivity analysis within the first 8 years of follow-up and thus including fewer events (n=222). Possibly, our risk estimate for substitution of SFA with cis-MUFA could be a reflection of the presence of residual confounding by TFA, which during the early 1990s was still a larger fraction of total MUFA intake. The nonsignificant association with CHD for the substitution of SFA with carbohydrates in our study did not change when taking into account the carbohydrate quality. These findings fit the existing evidence up to now, which is inconclusive, both on the effects on CHD risk of substitution of SFA with total carbohydrates 8, 15, 20 and on the effects of substitution of SFA with carbohydrates differing in quality. 9, 15, 20 Even though we did not observe conclusive effects of substituting macronutrients, other than animal protein, we cannot exclude the possibility that other substitution effects exist. The method used for substitution in observational studies like ours may not be ideal to answer this study question. §Additional adjustment for intakes of trans-fat, vegetable protein, animal protein (all in en%), and energy-adjusted intakes of cholesterol, fiber, and vitamin C.
‖Additional adjustment for the sum of all other SFA.
Although our study design was longitudinal, substitution of macronutrients was statistically modeled using dietary data that were derived at one time point. Thus, the replacement of macronutrients within subjects was not actually occurring, but rather a simultaneous comparison. Subjects with a relatively high intake of SFA, and a relatively low intake of another macronutrient, such as PUFA, were compared with subjects with a relatively high intake of PUFA and a relatively low intake of SFA. In our study, there was no other option, because we only had baseline dietary data available. However, up to now, in the limited number of studies that do have repeated dietary measures, the statistical modeling of substitution is done in a similar, simultaneous fashion. 9 The only difference lies in the fact that they repeat the substitution modeling for each time point, at which the dietary intake was measured. Furthermore, with interquartile ranges of 13.5 to 18.0 en% for SFA and 4.9 to 8.8 en% for PUFA, the variation in the intake range of PUFA across the SFA intake distribution in our study may not have been large enough to model the intended substitution. An experimental study design would be ideal, but is often not feasible, to study substitution effects on clinically manifest disease. Therefore, to gain more insight on this matter, it is necessary to investigate to what extent simultaneous baseline measures of macronutrients in observational studies represent real-life substitution and whether they provide suitable data to model the effects of substitution. Such an investigation would be achievable in a large cohort with long follow-up time and repeated dietary measures. Given the high costs of cardiovascular disease in terms of healthcare expenditure and quality of life, prevention strategies are paramount. Dietary factors are important modifiable risk factors that can be targeted for the prevention of cardiovascular diseases. Our study adds to the existing evidence, which together suggest that not total SFA intake but the type and source may be important in terms of cardiovascular disease risk. However, to be able to facilitate dietary recommendations related to saturated fat intake and related foods, future studies should determine whether dietary interventions to reduce saturated fat from specific food sources or with particular chain lengths could indeed have a beneficial effect on cardiovascular health.
Strengths of our study include the prospective study design, the large size of the study population, and the long follow-up time. One of its limitations is the use of an FFQ, which relies on self-report and is therefore subject to measurement error. A validation study of the FFQ showed that compared with the dietary history method, its relative validity for the measurement of total SFA was moderate, with a correlation coefficient of 0.39. 21 In case of subject misclassification, this is likely unrelated to the outcome and thus nondifferential, which generally leads to bias toward the null. 22 This may explain why we did not observe an association between total SFA intake and CHD. Also, the observed associations in our study therefore may actually be stronger. Second, we used baseline dietary measurements only, under the assumption that 2 decades of follow-up is an appropriate exposure time window for this study. Sensitivity analysis showed that during a shorter follow-up time of the first 8 years only, some of the observed associations became stronger. This could either indicate that the exposure time window was too long or may reflect changes in eating behavior or food composition. Dietary stability was not assessed in our study population, but results from the Dutch food consumption surveys showed changes in the diet of the general Dutch population between 1987 and 2010. In general, a shift was observed from high-fat dairy to low-fat dairy and from unprocessed to processed meat. 23 Nevertheless, it was shown by others that the association between dietary fatty acids and cardiovascular disease risk are fairly similar when using a baseline measurements versus dietary assessment close the outcome. 24 The population we used for the present analysis was free of cardiovascular disease at baseline, aged ≥55 years, and noninstitutionalized. Also, the major food sources of SFA intake were dairy (33%) and meat (18%). Therefore, the associations we observed may only be generalizable to a relatively healthy population of older age with a similar dietary pattern.
To conclude, the results of this study support the notion that in studies on the association between SFA and CHD, focusing on dietary SFA as a whole is too simplistic. Even though total SFA intake was not related to CHD risk in this prospective cohort study, and we observed no conclusive effect of SFA per food source, a higher intake of palmitic acid only was related to a higher CHD risk. Also, substitution of SFA with animal protein was associated with a higher risk of CHD. Translation of our findings to nutritional guidelines would be too premature, considering that the existing evidence up to now is limited and inconsistent. However, in future studies on SFA and CHD, it is of importance to consider the type of SFA and its substituting macronutrient. Furthermore, we need to investigate to what extent substitution modeling in observational data is feasible.
